503A vs 503B: The Two Kinds of Compounder the Law Allows
One sentence from a compliance guide, read like a contract, shows that a single prescription separates a pharmacy from a near-manufacturer.

I spent part of this week with one sentence from a compliance guide, and I have come to believe it contains most of American drug compounding in about fifty words. The guide is titled “503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations,” and here is the sentence: “503A pharmacies compound only against patient-specific prescriptions and must comply with USP <795> and <797> plus state board rules; 503B outsourcing facilities may produce large batches without patient-specific prescriptions but must comply with full CGMP under 21 CFR Parts 210 and 211.”
The plain answer first. A 503a pharmacy is a state-licensed pharmacy (or a federal facility, or a licensed physician) that mixes a drug for a particular, named patient on a prescription, and it is overseen mainly by its state board of pharmacy rather than the FDA. A 503B outsourcing facility is the other kind of compounder the law allows: it may make large batches without individual prescriptions, and in exchange it registers with the FDA, follows manufacturing-grade rules called CGMP, and gets inspected. That is the summary. The sentence is more interesting than the summary, so let’s read it like a contract.
What a 503A pharmacy is allowed to do, clause by clause
“503A pharmacies compound.” Fine. Under the statute, that compounding has to be “performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician,” as the law firm ArentFox Schiff summarizes Section 503A. So far this is just a description of a pharmacist doing pharmacist stuff.
“Only against patient-specific prescriptions.” I love the word “against.” It is the word you use for drawing against a credit line, and it fits: every vial a 503A pharmacy makes is drawn against a specific prescription for a specific person, and the prescription is sort of the collateral. No prescription, no vial. The guide’s other formulation is that 503A pharmacies “are designated as those that compound according to prescriptions specific to particular patients,” which is the same idea with less banking in it.
“Must comply with USP <795> and <797> plus state board rules.” Those are the standards for nonsterile and sterile compounding, plus whatever the state board wants. Now notice what is missing from the clause.
The FDA.
That absence is the whole point. A 503A pharmacy is not required to register with the FDA, and a pharmacy compounding under 503A for a patient-specific prescription is exempt from the federal CGMP framework in 21 CFR Parts 210 and 211. Read that exemption literally, though, and it has a condition baked in: it applies to compounding “for a patient-specific prescription.” The exemption does not belong to the building. It travels with the prescription.
Why the patient’s name does so much work at a 503A pharmacy
The intuitive way to describe this is that 503A is the small compounder and 503B is the big one. Actually, no. The sentence never says small. It says patient-specific, and those are different words that happen to point in the same direction most of the time.
Here is an invented example, clearly made up. Imagine a 503A pharmacy in a mid-sized city where, through some combination of telehealth and enthusiasm, 40,000 residents each hold a valid prescription for the same compounded injection. Every vial is labeled with a real person’s name. Every vial is drawn against a real prescription. The pharmacy runs three shifts, buys a second building, and installs a conveyor belt, and each item on the conveyor belt is still, technically, a bespoke preparation for Ms. Jane Doe of Elm Street (and her 39,999 neighbors). Literally, the clause is satisfied. In spirit, the place is presumably a factory that happens to hold a pharmacy license.
Where the law draws a numerical line on 503A volume is something the sources I’m working from do not settle; they describe the limit as the prescription requirement itself rather than as a number of units. The structural point holds either way: the 503A deal is that you get light federal oversight because you are doing something small and personal, and the prescription is the proof that it is small and personal. It is the cheapest possible compliance document. Somebody has to write it, though.
The everyday version is the difference between a diner cook and a frozen-pizza plant. Nobody inspects the diner cook’s process with the same rulebook as the pizza plant, because the cook is making one pizza for the person in booth four (who has never once asked to see a stability study). If the cook started shipping 40,000 pizzas a week, people would start asking pizza-plant questions.
What a 503B outsourcing facility gets for its paperwork
Now the second half. “503B outsourcing facilities may produce large batches.” The verb is “may,” which is permission, and “large batches” is the thing 503A could not quite do. “Without patient-specific prescriptions”: elsewhere the guide says “with or without prescriptions,” which is more accurate and also funnier, because it means the prescription has gone from collateral to optional.
“But must comply with full CGMP under 21 CFR Parts 210 and 211.” That “but” is the price. Section 501(a)(2)(B) of the Food, Drug, and Cosmetic Act requires outsourcing facilities to follow current good manufacturing practice, and they must also register with the FDA and submit to regular inspections, on top of state board rules. In exchange for giving up the patient’s name, they take on a manufacturer’s obligations.
Those obligations get specific. The FDA’s draft CGMP guidance for outsourcing facilities expects beyond-use dates (roughly, the date after which you should not use the stuff) to be supported by formulation-specific stability data, rather than the default categories a 503A pharmacy may rely on under USP <797>. (I have now read more about beyond-use dates than any person who writes jokes for a living probably should.) So the 503A pharmacist can look up a default date, and the 503B facility has to prove its date. I feel like I can hear the auditor: “Great, love the label, now show me the stability study for this exact formulation.”
One more thing the clause leaves out: approval. 503B facilities, for all their registration and inspection, “still do not produce FDA-approved medications.” They also face a bulks-list requirement for the raw ingredients they compound from, and tirzepatide, for instance, is not on the FDA’s Bulks List for 503B facilities or its Interim Bulks List. Big batches, manufacturing rules, and still not an approved drug.
What neither kind of compounder is allowed to copy
Both halves of the sentence share an unwritten clause: neither 503A nor 503B generally lets a compounder make a drug that is a copy of a commercially available, FDA-approved product. The exception is shortage. While the approved drug is on the FDA’s shortage list, compounders may fill the gap, and ArentFox Schiff’s description of the 503B version has a phrase worth reading literally: the drug must be on the list “at the time of compounding, distribution, and dispensing.” Three moments, all of which must be true. Not “once” or “recently.” (That is a lot to ask of a list.)
That is how the GLP-1 compounding boom worked and how it ended, which other articles on this site cover in detail. The short version is that the FDA’s February 21, 2025 declaratory order resolved the semaglutide injection shortage, and then the agency exercised what lawyers call enforcement discretion, a phrase that sounds like something you would want from a hotel concierge. 503A pharmacies got 60 days, to April 22, 2025. 503B facilities got 90, to May 22, 2025.
The gap is sort of revealing. The bigger, more regulated compounder got the longer runway, presumably because it had bigger batches and more customers to unwind. And in May 2026 the FDA proposed a rule that, if finalized, would close the last remaining pathway for large-scale 503B compounding of semaglutide, tirzepatide and liraglutide. Big machine, slow brakes.
Why everyone in this sentence is acting sensibly
It is tempting to read all this as dumb bureaucracy, but each party is doing the reasonable thing from where it sits. The FDA does not want to inspect every pharmacist making one cream for one patient, and it very much wants to inspect anything that looks like a factory. Pharmacies want to serve patients who show up with prescriptions, and outsourcing facilities want scale and will accept the inspections as the cost of it. Patients during a shortage wanted the drug that was unavailable, lol, which is not a complicated position.
The result is a regulatory regime that sorts compounders by one document. With it, you are a pharmacy. Without it, you are a manufacturer, almost.
The prescription is the whole difference.
Sources
- 503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations
- DEA Registration Requirements for Compounding Pharmacies
- cGMP Expectations for Outsourcing Facilities
- The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
- Semaglutide Salt Forms: Why the Base Matters
- The FDA Removes Semaglutide from the Drug Shortage List
- Compounding After a Drug Leaves the Shortage List
- GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner
- FDA's Semaglutide Shortage Resolution: Legal Implications And Risks For Compounding Pharmacies | Legal 500
- Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
- Alert to All Compounders: Update in FDA Tirzepatide Litigation - Frier Levitt
Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.